Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.56 |
| ▸ | MPO | P05164 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100011 | 0.86 | TAAR1 (0.56) | TAAR1HSPA5MPOCYP2D6TSHR | |
| SCHEMBL11208340 | 0.84 | TAAR1 (0.54) | TAAR1HSPA5MPOCYP2D6TSHR | |
| SCHEMBL29706272 | 0.84 | TAAR1 (0.71) | TAAR1HSPA5MPOCYP2D6TSHR | |
| SCHEMBL1222973 | 0.84 | TAAR1 (0.71) | TAAR1HSPA5MPOCYP2D6TSHR | |
| SCHEMBL29127699 | 0.82 | MGLL (0.56) | TAAR1HSPA5MPOCYP2D6TSHR | |
| SCHEMBL30081968 | 0.82 | MGLL (0.56) | TAAR1HSPA5MPOCYP2D6TSHR | |
| SCHEMBL30081969 | 0.82 | MGLL (0.56) | TAAR1HSPA5MPOCYP2D6TSHR | |
| SCHEMBL30695738 | 0.82 | MGLL (0.56) | TAAR1HSPA5MPOCYP2D6TSHR | |
| SCHEMBL29706378 | 0.81 | TAAR1 (0.68) | TAAR1HSPA5MPOCYP2D6TSHR | |
| SCHEMBL28445878 | 0.81 | IAPP (0.55) | TAAR1HSPA5CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1145353-A | Epoxy resin, resin composition, and resin-encapsulated semiconductor device | SUMITOMO CHEMICAL CO (JP) | 1997-03-19 | — | — | CN | claimed |
| JP-7033701-A | — | — | None | — | — | JP | disclosed |
| CN-109651094-A | A kind of preparation method of p- (2- methoxyl group) ethyl -phenol | 浙江永太科技股份有限公司 | 2019-04-19 | — | — | CN | disclosed |
| CN-1143858-C | 6, 9-disubstituted 2- [ trans- (aminocyclohexyl) amino ] purines, compositions and uses thereof | ������ҩ������˾ | 2004-03-31 | — | — | CN | disclosed |
| US-6642231-B2 | Antineoplastic agents, treatment for neuronal injury and degeneration | AVENTIS PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1056744-B1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| CN-1292789-A | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AWANDIS PHARMACEUTICAL CORP (US) | 2001-04-25 | — | — | CN | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| CN-1145353-A | Epoxy resin, resin composition, and resin-encapsulated semiconductor device | SUMITOMO CHEMICAL CO (JP) | 1997-03-19 | — | — | CN | disclosed |
| JP-H0733701-A | T-BUTOXYPHENETHYL CHLORIDE AND ITS PRODUCTION | HOKKO CHEM IND CO LTD | 1995-02-03 | — | — | JP | disclosed |
| US-4058566-A | Separation of isomers of phenols and phenolic ethers | UOP INC. (US) | 1977-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | TAAR1 3404/4885HSPA5 3992/4885MPO 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.